These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564 [TBL] [Abstract][Full Text] [Related]
45. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992 [TBL] [Abstract][Full Text] [Related]
46. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ; Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561 [TBL] [Abstract][Full Text] [Related]
47. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841 [TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ; Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072 [TBL] [Abstract][Full Text] [Related]
49. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Ku YH; Chuang YC; Yu WL J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741 [TBL] [Abstract][Full Text] [Related]
51. [Treatment with the first glycylcycline--tigecycline]. Musch A Med Monatsschr Pharm; 2006 May; 29(5):191-2. PubMed ID: 16719269 [No Abstract] [Full Text] [Related]
52. What role for tigecycline in infections? BMJ Group Drug Ther Bull; 2008 Aug; 46(8):62-4. PubMed ID: 18687585 [TBL] [Abstract][Full Text] [Related]
53. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Garrison MW; Mutters R; Dowzicky MJ Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459 [TBL] [Abstract][Full Text] [Related]
54. [Reduced risk of complications associated with severe acute (necrotizing) pancreatitis by administration of antibiotics; results from a literature review]. Lieverse RJ Ned Tijdschr Geneeskd; 2002 Mar; 146(11):535. PubMed ID: 11925810 [No Abstract] [Full Text] [Related]
55. [Reduced risk of complications associated with severe acute (necrotizing) pancreatitis by administration of antibiotics; results from a literature review]. te Velde LF; Ponssen HH; Koopman-van Gemert AW Ned Tijdschr Geneeskd; 2002 Mar; 146(11):534-5. PubMed ID: 11925809 [No Abstract] [Full Text] [Related]
56. [Bacterial resistance and a new antibiotic: tigecycline]. Gobernado M Rev Esp Quimioter; 2006 Sep; 19(3):209-19. PubMed ID: 17099789 [No Abstract] [Full Text] [Related]
57. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Denys GA; Koch KM; Dowzicky MJ Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143 [TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R; Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531 [TBL] [Abstract][Full Text] [Related]
60. A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia. Yılmaz Duran F; Yıldırım H; Şen EM Turk J Haematol; 2018 Mar; 35(1):83-84. PubMed ID: 29212626 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]